Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.40 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898437 | 1.00 | CTSS (0.50) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL30765049 | 1.00 | CTSS (0.50) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL30765047 | 1.00 | CTSS (0.50) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL31703417 | 0.91 | CTSS (0.50) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL864799 | 0.89 | PTPN1 (0.54) | CTSSCTSKPTPN1SCN9AACE | |
| SCHEMBL31494602 | 0.89 | CTSS (0.51) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL864800 | 0.89 | PTPN1 (0.54) | CTSSCTSKPTPN1SCN9AACE | |
| SCHEMBL30765042 | 0.89 | PTPN1 (0.54) | CTSSCTSKPTPN1SCN9AACE | |
| SCHEMBL20235970 | 0.88 | CTSS (0.50) | CTSSCTSKKLK5TACR1PTPN1 | |
| SCHEMBL20235969 | 0.88 | CTSS (0.50) | CTSSCTSKKLK5TACR1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | CTSS 1847/4885CTSK 1525/4885KLK5 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.